A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study
Open Access
- 27 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 13 (1), 561
- https://doi.org/10.1186/1471-2334-13-561
Abstract
Background: Acceptance of healthcare-associated pneumonia (HCAP) as an entity and the associated risk of infection by potentially multidrug-resistant (MDR) organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with HCAP, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) enrolled in a trial comparing linezolid with vancomycin for treatment of pneumonia. Methods: The analysis included all patients who received study drug. HCAP was defined as pneumonia occurring < 48 hours into hospitalization and acquired in a long-term care, subacute, or intermediate health care facility; following recent hospitalization; or after chronic dialysis. Results: Data from 1184 patients (HCAP = 199, HAP = 379, VAP = 606) were analyzed. Compared with HAP and VAP patients, those with HCAP were older, had slightly higher severity scores, and were more likely to have comorbidities. Pseudomonas aeruginosa was the most common gram-negative organism isolated in all pneumonia classes [HCAP, 22/199 (11.1%); HAP, 28/379 (7.4%); VAP, 57/606 (9.4%); p = 0.311]. Acinetobacter spp. were also found with similar frequencies across pneumonia groups. To address potential enrollment bias toward patients with MRSA pneumonia, we grouped patients by presence or absence of MRSA and found little difference in frequencies of Pseudomonas and Acinetobacter. Conclusions: In this population of pneumonia patients, the frequencies of MDR gram-negative pathogens were similar among patients with HCAP, HAP, or VAP. Our data support inclusion of HCAP within nosocomial pneumonia guidelines and the recommendation that empiric antibiotic regimens for HCAP should be similar to those for HAP and VAP.Keywords
This publication has 34 references indexed in Scilit:
- Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort StudyClinical Infectious Diseases, 2011
- Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumoniaJournal of Antimicrobial Chemotherapy, 2011
- Guideline-concordant therapy and outcomes in healthcare-associated pneumoniaEuropean Respiratory Journal, 2011
- Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospitalBMC Infectious Diseases, 2011
- Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort studyThe Lancet Infectious Diseases, 2011
- Characteristics and disease severity of healthcare-associated pneumonia among patients in a hospital in Kitakyushu, JapanJournal of Infection and Chemotherapy, 2011
- Rethinking the concepts of community-acquired and health-care-associated pneumoniaThe Lancet Infectious Diseases, 2010
- Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: Results of the Eole studyCritical Care Medicine, 2002
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- The Diagnosis of Ventilator-Associated PneumoniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1997